Hal Cohen | Feb 23, 2003 | 3 min read
Systems biology, a siren in a sea of dark prospects, has lured investors frustrated with low returns in biotechnology and anxious to set a new course of drug discovery. Institutions have also geared up training programs, but the excitement in the new field has failed to arrest downsizing in the biotech industry. Major research institutions and pharmaceutical companies, including AstraZeneca, Novartis, and Eli Lilly and Company, are implementing systems biology in the hopes of slashing drug di